Stephen B. Tatter

AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial

Peter A. LeWitt, Ali R. Rezai, Maureen A. Leehey et al. · The Lancet Neurology · 2011 · 661 citations

Advanced Parkinson, Aav2-gad Gene Therapy, Neurological Progress +5

A Phase I Open-Label, Dose-Escalation, Multi-Institutional Trial of Injection with an E1B-Attenuated Adenovirus, ONYX-015, into the Peritumoral Region of Recurrent Malignant Gliomas, in the Adjuvant Setting

E. Antonio Chiocca, Khalid M. Abbed, Stephen B. Tatter et al. · Molecular Therapy · 2004 · 434 citations · Full text

Predictors of Successful Extubation in Neurosurgical Patients

ANDREW M. NAMEN, E. Wesley Ely, Stephen B. Tatter et al. · American Journal of Respiratory and Critical Care Medicine · 2001 · 341 citations

Pulmonary Care, Surgery, Respiratory Therapy +16

Endotoxemia elicits increased circulating <i>beta</i>  2-IFN/IL-6 in man.

Yuman Fong, Lyle L. Moldawer, Michael A. Marano et al. · The Journal of Immunology · 1989 · 325 citations

Synthesis and secretion of multiple forms of beta 2-interferon/B-cell differentiation factor 2/hepatocyte-stimulating factor by human fibroblasts and monocytes.

L T May, John Ghrayeb, Uma Santhanam et al. · Journal of Biological Chemistry · 1988 · 251 citations · Full text